These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20373694)

  • 1. [Statin prescription in primary prevention: which cardiovascular risk score should be used in Switzerland?].
    Nanchen D; Chiolero A; Marques-Vidal PM; Cornuz J; Waeber G; Vollenweider P; Rodondi N
    Rev Med Suisse; 2010 Mar; 6(239):488-90, 492-3. PubMed ID: 20373694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the change in the Framingham Risk Score calculator between the 2006 and 2009 Canadian lipid guidelines.
    Armstrong DW; Brouillard D; Matangi MF
    Can J Cardiol; 2011; 27(2):167-70. PubMed ID: 21459264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular risk assessment by primary-care physicians in Germany and its lack of agreement with the Established Risk Scores (DETECT)].
    Silber S; Jarre F; Pittrow D; Klotsche J; Pieper L; Zeiher AM; Wittchen HU;
    Med Klin (Munich); 2008 Sep; 103(9):638-45. PubMed ID: 18813887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What do the statins tell us?
    LaRosa JC
    Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Socioeconomic aspects of therapy of cardiovascular diseases].
    Lauterbach KW
    Herz; 2000 Aug; 25(5):473-5. PubMed ID: 10992995
    [No Abstract]   [Full Text] [Related]  

  • 9. [Good prevention of type 2 diabetes with lipid-lowering statin therapy. Intervention studies support active treatment of risk patients].
    Nilsson PM; Attvall S; Båvenholm P
    Lakartidningen; 2004 Nov; 101(47):3798, 3801-2, 3804. PubMed ID: 15609534
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E; Harats D; Gavish D
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
    Tonstad S; Rosvold EO; Furu K; Skurtveit S
    J Intern Med; 2004 Apr; 255(4):494-502. PubMed ID: 15049884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
    Rudling M
    Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
    [No Abstract]   [Full Text] [Related]  

  • 14. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol].
    Carlson LA
    Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660
    [No Abstract]   [Full Text] [Related]  

  • 15. [How far the rates of cholesterol have to be lowered in primary prevention?].
    Rodondi N
    Rev Med Suisse; 2010 Mar; 6(239):483-4. PubMed ID: 20373693
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 18. Consequences of using different methods to assess cardiovascular risk in primary care.
    Fornasini M; Brotons C; Sellarès J; Martinez M; Galán ML; Sáenz I; da Pena JM
    Fam Pract; 2006 Feb; 23(1):28-33. PubMed ID: 16243952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
    Zamorano J; Erdine S; Lopez AP; Kim JH; Al Khadra A; Westergaard M; Sutradhar S; Yunis C;
    Postgrad Med; 2010 Mar; 122(2):7-15. PubMed ID: 20203451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.